Fintel reports that on October 27, 2023, Stephens & Co. maintained coverage of West Pharmaceutical Services (NYSE:WST) with a Overweight recommendation.
Analyst Price Forecast Suggests 24.87% Upside
As of October 4, 2023, the average one-year price target for West Pharmaceutical Services is 408.73. The forecasts range from a low of 328.25 to a high of $483.00. The average price target represents an increase of 24.87% from its latest reported closing price of 327.32.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for West Pharmaceutical Services is 2,899MM, a decrease of 0.94%. The projected annual non-GAAP EPS is 7.38.
What is the Fund Sentiment?
There are 1504 funds or institutions reporting positions in West Pharmaceutical Services. This is an increase of 33 owner(s) or 2.24% in the last quarter. Average portfolio weight of all funds dedicated to WST is 0.33%, an increase of 0.17%. Total shares owned by institutions decreased in the last three months by 2.43% to 78,686K shares. 
The put/call ratio of WST is 0.79, indicating a bullish outlook.
What are Other Shareholders Doing?
Bank of New York Mellon holds 3,389K shares representing 4.59% ownership of the company. In it's prior filing, the firm reported owning 3,440K shares, representing a decrease of 1.51%. The firm decreased its portfolio allocation in WST by 88.75% over the last quarter.
Price T Rowe Associates holds 2,838K shares representing 3.84% ownership of the company. In it's prior filing, the firm reported owning 2,843K shares, representing a decrease of 0.17%. The firm increased its portfolio allocation in WST by 2.58% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,312K shares representing 3.13% ownership of the company. In it's prior filing, the firm reported owning 2,294K shares, representing an increase of 0.78%. The firm increased its portfolio allocation in WST by 2.65% over the last quarter.
APG Asset Management N.V. holds 2,260K shares representing 3.06% ownership of the company. In it's prior filing, the firm reported owning 2,385K shares, representing a decrease of 5.54%. The firm decreased its portfolio allocation in WST by 0.98% over the last quarter.
Franklin Resources holds 2,174K shares representing 2.94% ownership of the company. In it's prior filing, the firm reported owning 2,288K shares, representing a decrease of 5.27%. The firm decreased its portfolio allocation in WST by 0.65% over the last quarter.
West Pharmaceutical Services Background Information
(This description is provided by the company.)
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With almost 10,000 team members across 50 sites worldwide, West helps support its customers by delivering over 40 billion components and devices each year.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
